​

Beta Bionics (BBNX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BBNX Stock Forecast

Beta Bionics (BBNX) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $24.67, with a high of $30.00 and a low of $16.00. This represents a 59.26% increase from the last price of $15.49.

$10 $15 $20 $25 $30 $35 High: $30 Avg: $24.67 Low: $16 Last Closed Price: $15.49

BBNX Stock Rating

Beta Bionics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (66.67%), 3 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 3 6 0 Strong Sell Sell Hold Buy Strong Buy

BBNX Price Target Upside V Benchmarks

TypeNameUpside
StockBeta Bionics59.26%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks9.18%

Price Target Trends

1M3M12M
# Anlaysts3823
Avg Price Target$28.00$25.38$24.35
Last Closing Price$15.49$15.49$15.49
Upside/Downside80.76%63.85%57.20%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 26294--15
Oct, 26184--13
Sep, 26174--12
Aug, 26173--11
Jul, 26173--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 28, 2026Matt O'BrienPiper Sandler$24.00$21.3912.20%54.94%
Oct 12, 2026Michael ToomeyJefferies$30.00$17.6370.16%93.67%
Oct 06, 2026Christopher PasqualeBarclays$30.00$18.6361.03%93.67%
Sep 23, 2026Wells Fargo$28.00$22.8122.75%80.76%
Sep 15, 2026Richard NewitterTruist Financial$23.00$16.7337.48%48.48%
Sep 15, 2026Robert W. Baird$16.00$16.73-4.36%3.29%
Sep 15, 2026UBS$25.00$16.7349.43%61.39%
Sep 14, 2026Mike KratkyLeerink Partners$27.00$17.5354.02%74.31%
Jul 28, 2026Patrick WoodUBS$22.00$15.9937.59%42.03%
Jul 15, 2026Goldman Sachs$19.00$16.8612.69%22.66%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 28, 2026Cowen & Co.HoldHoldhold
Oct 28, 2026Piper SandlerOverweightOverweighthold
Oct 12, 2026JefferiesBuyinitialise
Oct 06, 2026BarclaysOverweightinitialise
Sep 23, 2026Wells FargoOverweightinitialise
Sep 15, 2026UBSBuyBuyhold
Aug 21, 2026William BlairMarket Performinitialise
Jul 15, 2026Goldman SachsBuyBuyhold
Mar 24, 2026Lake StreetBuyBuyhold
Feb 08, 2026UBSBuyinitialise

Financial Forecast

EPS Forecast

$-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-8.60$-1.81----
Avg Forecast$-2.13$-1.84$-1.96$-2.03$-1.61$-0.95
High Forecast$-1.74$-1.37$-1.52$-0.65$-1.53$-0.90
Low Forecast$-2.75$-2.04$-2.20$-2.72$-1.68$-0.99
Surprise %303.76%-1.63%----

Revenue Forecast

$50M $100M $150M $200M $250M $300M Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$65.12M$100.25M----
Avg Forecast$64.87M$82.68M$111.56M$150.21M$206.79M$270.39M
High Forecast$65.20M$84.80M$116.46M$150.21M$214.26M$280.16M
Low Forecast$63.79M$80.70M$106.20M$150.21M$198.97M$260.17M
Surprise %0.39%21.25%----

Net Income Forecast

$-75M $-60M $-45M $-30M $-15M $0 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-54.76M$-73.20M----
Avg Forecast$-14.28M$-10.83M$-11.85M$-10.73M$-10.22M$-6.05M
High Forecast$-11.05M$-8.71M$-9.70M$-4.11M$-9.71M$-5.75M
Low Forecast$-17.51M$-12.96M$-13.99M$-17.34M$-10.70M$-6.33M
Surprise %283.51%575.72%----

BBNX Forecast FAQ

Is Beta Bionics stock a buy?

Beta Bionics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Beta Bionics is a favorable investment for most analysts.

What is Beta Bionics's price target?

Beta Bionics's price target, set by 9 Wall Street analysts, averages $24.67 over the next 12 months. The price target range spans from $16 at the low end to $30 at the high end, suggesting a potential 59.26% change from the previous closing price of $15.49.

How does Beta Bionics stock forecast compare to its benchmarks?

Beta Bionics's stock forecast shows a 59.26% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (9.18%).

What is the breakdown of analyst ratings for Beta Bionics over the past three months?

  • November 2026: 13.33% Strong Buy, 60.00% Buy, 26.67% Hold, 0% Sell, 0% Strong Sell.
  • October 2026: 7.69% Strong Buy, 61.54% Buy, 30.77% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 8.33% Strong Buy, 58.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Beta Bionics’s EPS forecast?

Beta Bionics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.96, marking a 8.29% increase from the reported $-1.81 in 2025. Estimates for the following years are $-2.03 in 2027, $-1.61 in 2028, and $-0.95 in 2029.

What is Beta Bionics’s revenue forecast?

Beta Bionics's average annual revenue forecast for its fiscal year ending in December 2026 is $111.56M, reflecting a 11.28% increase from the reported $100.25M in 2025. The forecast for 2027 is $150.21M, followed by $206.79M for 2028, and $270.39M for 2029.

What is Beta Bionics’s net income forecast?

Beta Bionics's net income forecast for the fiscal year ending in December 2026 stands at $-11.846M, representing a -83.82% decrease from the reported $-73.2M in 2025. Projections indicate $-10.726M in 2027, $-10.216M in 2028, and $-6.047M in 2029.